Cost-Effectiveness Analysis of Camrelizumab Immunotherapy versus Docetaxel or Irinotecan Chemotherapy as Second-Line Therapy for Advanced or Metastatic Esophageal Squamous Cell Carcinoma
Ying-Tao Lin,1 Ying Chen,2 Tian-Xiu Liu,3 Fang Kuang,1 Ping Huang1 1Administration Office of Drug Clinical Trial, Fujian Medical University Cancer Hospital, Fujian Cancer Hospital, Fuzhou, People’s Republic of China; 2Management Office of Science and Technology, Fujian Medical University Cancer Hosp...
Gardado en:
| Principais autores: | , , , , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado: |
Dove Medical Press
2021-11-01
|
| Series: | Cancer Management and Research |
| Assuntos: | |
| Acceso en liña: | https://www.dovepress.com/cost-effectiveness-analysis-of-camrelizumab-immunotherapy-versus-docet-peer-reviewed-fulltext-article-CMAR |
| Tags: |
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|